Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Pooja SandujaDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Stefanie S SchmiederDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Buket BaddalDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Songhai TianDepartment of Urology, Boston Children's Hospital, Boston, Massachusetts, USA.
Jorge J VelardeDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Wayne I LencerDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Min DongDepartment of Urology, Boston Children's Hospital, Boston, Massachusetts, USA.
Michael R WesselsDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-7494-4723
Funding
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
Mechanism of action for the epithelial-specific ER stress sensor IRE1β in regulating intestinal homeostasis and host defenseR01DK048106 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI WAYNE I LENCER · 1993 to 2026
$9.6M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Intestinal Disease-enterocyte toxin interactionR37DK048106 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LENCER, WAYNE I · 2011 to 2020
$7.0M
Pain and Neuro-immune Signaling in S. pyogenes pathogenesisR01AI130019 · NIAID · HARVARD MEDICAL SCHOOL · PI CHIU, ISAAC MING-CHENG, WESSELS, MICHAEL R · 2017 to 2021
$3.2M
Mechanisms of action for the IBD-risk gene INAVA: an epithelial guard receptor for inflammation and integrity of the intestinal barrierR01DK122953 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LENCER, WAYNE I · 2020 to 2023
$2.0M
Structure and Function Studies of LL-37 Binding to CsrS of Group A StreptococcusK08AI112823 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI VELARDE, JORGE J · 2016 to 2020
$939k
Charles A. King Trust Postdoctoral FellowshipHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI112823HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI130019HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK 048106, DK122953, DK 034854NIAID NIH HHS K08 AI112823NIAID NIH HHS R01 AI130019NICHD NIH HHS P50 HD105351NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK048106NIDDK NIH HHS R01 DK122953NIDDK NIH HHS R37 DK048106
6 · The paper itself
Abstract
Streptolysin O (SLO) is a virulence determinant of group A IMPORTANCE: Group A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SLO co-opts host cell glycosphingolipids to access cholesterol-rich lipid rafts for enhanced pore formation and cytotoxicity. · full record | OpenQuestion